Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash from Operations (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Cash from Operations readings, the most recent being 30885.0 for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 47.32% to 30885.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 29133.0, a 75.06% increase, with the full-year FY2024 number at 123077.0, down 8.77% from a year prior.
  • Cash from Operations hit 30885.0 in Q3 2025 for Goldenwell Biotech, down from 59380.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 59380.0 in Q2 2025 to a low of 917090.0 in Q4 2022.
  • Median Cash from Operations over the past 5 years was 29010.0 (2024), compared with a mean of 86571.16.
  • Biggest five-year swings in Cash from Operations: crashed 105675.35% in 2021 and later soared 224.35% in 2025.
  • Goldenwell Biotech's Cash from Operations stood at 19373.0 in 2021, then plummeted by 4633.86% to 917090.0 in 2022, then soared by 97.92% to 19076.0 in 2023, then plummeted by 32.89% to 25351.0 in 2024, then decreased by 21.83% to 30885.0 in 2025.
  • The last three reported values for Cash from Operations were 30885.0 (Q3 2025), 59380.0 (Q2 2025), and 32277.0 (Q1 2025) per Business Quant data.